Supply Chain Intelligence

Climb Bio, Inc. Supply Chain

CLYM supply chain intelligence for Climb Bio, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

CLYM ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

5Suppliers
25Customers
2Debt Items
20Related Chains

Source-Backed Evidence Depth

Climb Bio, Inc. (CLYM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

33Total relationships
2Distinct source URLs
7High confidence
0.734Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Climb Bio, Inc. Suppliers

TickerNameConfidenceEvidence
RA-CAPITAL-MANAGEMENT-L-P RA-CAPITAL-MANAGEMENT-L-P 92% the Company agreed to issue and sell to the Investors in a private placement an aggregate of 9,481,000 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of …
OPPENHEIMER-CO-INC OPPENHEIMER-CO-INC 90% In March 2025, we entered into an Equity Distribution Agreement (the Distribution Agreement) with Oppenheimer & Co. Inc., as agent (Oppenheimer), pursuant to which we may offer and sell shares of our…
BEIJING-MABWORKS-BIOTECH-CO-LTD BEIJING-MABWORKS-BIOTECH-CO-LTD 85% the ability of the Company to timely and successfully achieve or recognize the anticipated benefits of its technology transfer and exclusive license agreement with Beijing Mabworks Biotech Co., Ltd.
ALMS Alumis Inc. 72% Reciprocal relationship from ALMS graph: ted ACELYRIN stock options and RSUs continue to vest in accordance with their original terms. Performance RSUs were deemed to have 100 % satisfied their perfo…
JBIO Jade Biosciences, Inc. 72% Reciprocal relationship from JBIO graph: fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we: 39 • advance our e…

Climb Bio, Inc. Customers

TickerNameConfidenceEvidence
RA-CAPITAL-MANAGEMENT-L-P RA-CAPITAL-MANAGEMENT-L-P 92% the Company agreed to issue and sell to the Investors in a private placement an aggregate of 9,481,000 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of …
CABA Cabaletta Bio, Inc. 72% ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r…
CABA Cabaletta Bio, Inc. 72% Reciprocal relationship from CABA graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from CABA graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from CABA g…
CGEM Cullinan Therapeutics, Inc. 72% ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r…
CGEM Cullinan Therapeutics, Inc. 72% Reciprocal relationship from CGEM graph: Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate…
JBIO Jade Biosciences, Inc. 72% Reciprocal relationship from JBIO graph: Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate…
JBIO Jade Biosciences, Inc. 72% ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r…
KYTX Kyverna Therapeutics, Inc. 72% Reciprocal relationship from KYTX graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical stud…
KYTX Kyverna Therapeutics, Inc. 72% ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r…
TKPHF Takeda Pharmaceutical Company Limited 72% ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r…
TKPHF Takeda Pharmaceutical Company Limited 72% Reciprocal relationship from TKPHF graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from TKPH…
VERA Vera Therapeutics, Inc. 72% ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r…
VERA Vera Therapeutics, Inc. 72% Reciprocal relationship from VERA graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from VERA graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from VERA g…
VRTX Vertex Pharmaceuticals Incorporated 72% Reciprocal relationship from VRTX graph: Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate…
VRTX Vertex Pharmaceuticals Incorporated 72% ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r…
ZBIO Zenas BioPharma, Inc. 72% ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate; • clinical trials of our product candidates producing negative or inconclusive r…
ZBIO Zenas BioPharma, Inc. 72% Reciprocal relationship from ZBIO graph: Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical studies and clinical trials of our product candidates being greater than we anticipate…
CANCER-RESEARCH-TECHNOLOGY-LIMITED CANCER-RESEARCH-TECHNOLOGY-LIMITED 62% ly affected. • We face significant competition in an environment of rapid technological change, and our competitors may develop or obtain regulatory approval for products before us or develop product…
CLMB Climb Global Solutions, Inc. 62% Reciprocal relationship from CLMB graph: Reciprocal relationship from CLYM graph: ions and Basis of Presentation Organization Climb Bio, Inc. (the Company), is a clinical-stage biotechnology company …
DELAWARE-GENERAL-CORPORATION DELAWARE-GENERAL-CORPORATION 62% that may enhance our capabilities, complement our existing products and technologies or expand the breadth of our markets or customer base. For example, we entered into the Mabworks Agreement where w…
PRESENTATION-ORGANIZATION-CLIMB-BIO-INC PRESENTATION-ORGANIZATION-CLIMB-BIO-INC 62% ions and Basis of Presentation Organization Climb Bio, Inc. (the Company), is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s …
PROBIOGEN-AG PROBIOGEN-AG 62% proved products in other markets; • obtain coverage and adequate reimbursement from third-party payors, including government and private payors; • achieve market acceptance for any products; • establ…
QUARTERLY-REPORT-EMERGING-GROWTH-COMPANY QUARTERLY-REPORT-EMERGING-GROWTH-COMPANY 62% f regulatory requirements, regulatory submissions and timing of regulatory approvals; • the costs involved in prosecuting and enforcing patent and other intellectual property claims; • the potential …
TECHNOLOGY-LIMITED TECHNOLOGY-LIMITED 62% search Technology Limited (CRH). With respect to CLYM116, we have one exclusively in-licensed PCT application under the Mabworks Agreement and co-own three pending provisional patent applications wit…
TENET-MEDICINES-INC TENET-MEDICINES-INC 62% proved products in other markets; • obtain coverage and adequate reimbursement from third-party payors, including government and private payors; • achieve market acceptance for any products; • establ…

Climb Bio, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
CLYM-DEBT-8715 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.
CLYM-DEBT Debt stack $479,000 90% Market cache reports total debt of $479,000.

Climb Bio, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Climb Bio, Inc..

Climb Bio, Inc. Ownership

HolderNameConfidenceEvidence
CLYM-OWNER-RA-CAPITAL-MANAGEMENT-L-P RA CAPITAL MANAGEMENT, L.P. 90% 13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 83 tracked holders.

Climb Bio, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
GDTC CytoMed Therapeutics Limited 100.00 2
HOWL Werewolf Therapeutics, Inc. 100.00 2
BMY Bristol-Myers Squibb Company 100.00 2
BMYMP Bristol-Myers Squibb Co 100.00 2
CLLS Cellectis S.A. 100.00 2
HALO Halozyme Therapeutics, Inc. 100.00 2
COLL Collegium Pharmaceutical, Inc. 100.00 2
CLMB Climb Global Solutions, Inc. 100.00 1 ['customer']
BHC Bausch Health Companies Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
DNTH Dianthus Therapeutics, Inc. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
GILD Gilead Sciences, Inc. 100.00 2
AVBP ArriVent BioPharma, Inc. 100.00 2
FDMT 4D Molecular Therapeutics, Inc. 100.00 2
CRSP CRISPR Therapeutics AG 100.00 2
AUPH Aurinia Pharmaceuticals Inc. 100.00 2
ARTV Artiva Biotherapeutics, Inc. 100.00 2
INCY Incyte Corporation 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Climb Bio, Inc..

Unlock full CLYM data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
CLYM
Unlock CLYM Supply Chain Data
Verified relationships include:
RA-CAPITAL-MANAGEMENT-L-PRA-CAPITAL-MANAGEMENT-L-PSupplier92%
OPPENHEIMER-CO-INCOPPENHEIMER-CO-INCSupplier90%
RA-CAPITAL-MANAGEMENT-L-PRA-CAPITAL-MANAGEMENT-L-PCustomer92%
CABACabaletta Bio, Inc.Customer72%
+29 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →